Drugs for Hyper Ige Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 46)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Posaconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
171228-49-2 |
147912 |
Synonyms:
|
2 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
3 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
4 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
5 |
|
Hormones |
|
Phase 3 |
|
|
|
6 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
7 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
8 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
9 |
|
Antifungal Agents |
|
Phase 3 |
|
|
|
10 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
11 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
12 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
13 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
14 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
15 |
|
Ranitidine |
Approved, Withdrawn |
Phase 2 |
|
66357-59-3, 82530-72-1, 66357-35-5 |
3001055 5039 |
Synonyms:
(e)-Ranitidine
1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulphanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Achedos
Acidex
AH-19065|Gavilast®|GR-122311X|Zantac®
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
Atural
Axoban
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
Benadryl
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
Biotidin
Citrate, diphenhydramine
Coralen
Curan
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
Dimethyl[(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulphanyl]methyl}furan-2-yl)methyl]amine
Dimethylamine benzhydryl ester
Diphamine
Diphantine
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
Diphenhydramine hydrochloride
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
Duractin
Ezopta
Gastrial
Gastrosedol
Hydrochloride, diphenhydramine
Hydrochloride, ranitidine
Istomar
|
Logast
Mauran
Microtid
N (2-(((5-((dimethylamino)Methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
O-Benzhydryldimethylaminoethanol
Ptinolin
Quantor
Quicran
Radinat
RAN
Randin
Ranidine
Ranin
Raniogas
Ranisen
Raniter
Ranitidin
Ranitidina
Ranitidine
Ranitidine (form I and form II)
Ranitidine base
Ranitidine HCL 1/2 type
Ranitidine hydrochloride
Ranitidinum
Ranitiget
Rantacid
Rantidine
Ratic
Raticina
Restamin
RND
Sampep
Sostril
Taural
Tritec
Ulceranin
Ul-pep
Urantac
Verlost
Vesyca
Vizerul
Weichilin
Weidos
Xanidine
Zantab
Zantac
Zantadin
Zantic
Α-(2-dimethylaminoethoxy)diphenylmethane
Î’-dimethylaminoethanol diphenylmethyl ether
Î’-dimethylaminoethyl benzhydryl ether
|
|
16 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
17 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
18 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
19 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
20 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
21 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
22 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
23 |
|
Anesthetics |
|
Phase 2 |
|
|
|
24 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
25 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
26 |
|
Vaccines |
|
Phase 2 |
|
|
|
27 |
|
Agglutinins |
|
Phase 2 |
|
|
|
28 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
29 |
|
Antibodies |
|
Phase 2 |
|
|
|
30 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
31 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
32 |
|
Antacids |
|
Phase 2 |
|
|
|
33 |
|
Ranitidine bismuth citrate |
|
Phase 2 |
|
|
|
Synonyms:
GR-122311X
PYLORID
RANITIDINE BISMUTH CITRATE
|
RANITIDINE BISMUTREX
TRITEC
|
|
34 |
|
Histamine phosphate |
|
Phase 2 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
35 |
|
Histamine H2 Antagonists |
|
Phase 2 |
|
|
|
36 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
37 |
|
Bismuth tripotassium dicitrate |
|
Phase 2 |
|
|
|
38 |
|
Bismuth |
|
Phase 2 |
|
7440-69-9 |
105143 |
Synonyms:
Bi
Bi(3+)
Bismuth(III) cation
|
Bismuth-209
Bisumth(3+) ion
|
|
39 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
40 |
|
Citrate |
|
Phase 2 |
|
|
|
41 |
|
Omalizumab |
Approved, Investigational |
Phase 1 |
|
242138-07-4 |
|
Synonyms:
IG GAMMA-1 CHAIN C REGION
IGE025
IGE25
IGE25|olizumab|R03DX05|RG-3648|rhumab-E25|Xolair®
OLIZUMAB
|
OMALIZUMAB
RG-3648
RHUMAB-E25
XOLAIR
|
|
42 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
43 |
|
Anti-Asthmatic Agents |
|
Phase 1 |
|
|
|
44 |
|
Anti-Allergic Agents |
|
Phase 1 |
|
|
|
45 |
|
Respiratory System Agents |
|
Phase 1 |
|
|
|
46 |
|
Pharmaceutical Solutions |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
(show all 12)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections |
Completed |
NCT00033982 |
Phase 3 |
Posaconazole |
2 |
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency |
Recruiting |
NCT01176006 |
Phase 2 |
Fludarabine(Fludara, Berlex Laboratories);Cyclophosphamide(CTX, Cytoxan);Busulfan (Busulfex) |
3 |
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors |
Enrolling by invitation |
NCT01852370 |
Phase 1, Phase 2 |
|
4 |
A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome |
Terminated |
NCT02996448 |
Phase 2 |
NDV-3A |
5 |
A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations |
Terminated |
NCT00527878 |
Phase 2 |
Ranitidine;Placebo |
6 |
Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome |
Completed |
NCT00260702 |
Phase 1 |
Omalizumab (Xolair) |
7 |
Diagnostic Efficacy of Virtual Bronchoscopy |
Completed |
NCT00001515 |
Phase 1 |
|
8 |
NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE Syndrome |
Unknown status |
NCT02228941 |
|
|
9 |
Cognitive Function in Leukocyte Disorders |
Completed |
NCT00005933 |
|
|
10 |
Multicenter, Open, Prospective, Randomized Trial of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old |
Recruiting |
NCT04897113 |
|
|
11 |
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES) |
Recruiting |
NCT00006150 |
|
|
12 |
Skin Immunity Sample Collection Involving Blisters and Biopsies |
Not yet recruiting |
NCT03921515 |
Early Phase 1 |
|
|